(Q41424509)

English

Enhanced humoral and mucosal immune responses after intranasal immunization with chimeric multiple antigen peptide of LcrV antigen epitopes of Yersinia pestis coupled to palmitate in mice

scientific article published on 12 October 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Enhanced humoral and mucosal immune responses after intranasal immunization with chimeric multiple antigen peptide of LcrV antigen epitopes of Yersinia pestis coupled to palmitate in mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Yersinia pestis

0 references

object named as

Ajaz Ahmed Bhat

2

0 references

author name string

Srijayaprakash Babu Uppada

1

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Anil Sah

3

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Rao Nageswara Donthamshetty

4

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

language of work or name

0 references

publication date

12 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

50

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

9352-9360

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

A comparison of Plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Inducing systemic and mucosal immune responses to B-T construct of F1 antigen of Yersinia pestis in microsphere delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Oral vaccination against bubonic plague using a live avirulent Yersinia pseudotuberculosis strain.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Different strategies for preparation of non-tagged rV270 protein and its efficacy against Yersinia pestis challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

A plant-produced plague vaccine candidate confers protection to monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Immune defense against pneumonic plague

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Anti-V antigen antibody protects macrophages from Yersinia pestis -induced cell death and promotes phagocytosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Antibody against V antigen prevents Yop-dependent growth of Yersinia pestis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Oral vaccination with salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Lipid A mimetics are potent adjuvants for an intranasal pneumonic plague vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Protection against anthrax and plague by a combined vaccine in mice and rabbits

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Quantitative anti-F1 and anti-V IgG ELISAs as serological correlates of protection against plague in female Swiss Webster mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Hijacking of the pleiotropic cytokine interferon-γ by the type III secretion system of Yersinia pestis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Comparison of immunological responses of plague vaccines F1+rV270 and EV76 in Chinese-origin rhesus macaque, Macaca mulatta

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Evaluation of the humoral immune response in mice orally vaccinated with live recombinant attenuated Salmonella enterica delivering a secreted form of Yersinia pestis PsaA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Human anti-plague monoclonal antibodies protect mice from Yersinia pestis in a bubonic plague model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

A live attenuated strain of Yersinia pestis KIM as a vaccine against plague

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

IL-17 contributes to cell-mediated defense against pulmonary Yersinia pestis infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Identifying B and T cell epitopes and studying humoral, mucosal and cellular immune responses of peptides derived from V antigen of Yersinia pestis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Cell-mediated immune response and Th/Th cytokine profile of B-T constructs of F1 and V antigen of Yersinia pestis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

IgG surfaces as an important component in mucosal protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Tapping the immunological repertoire to produce antibodies of predetermined specificity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Protection of cattle against foot-and-mouth disease by a synthetic peptide.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Humoral immune responses and protective efficacy of sequential B- and T-cell epitopes of V antigen of Yersinia pestis by intranasal immunization in microparticles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

A multiple antigen peptide from the repetitive sequence of the Plasmodium malariae circumsporozoite protein induces a specific antibody response in mice of various H-2 haplotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Long-lasting anti-viral cytotoxic T lymphocytes induced in vivo with chimeric-multirestricted lipopeptides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Toward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis(y) conjugates in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Clinical evaluation of the immunoadjuvant murabutide, a derivative of MDP, administered with a tetanus toxoid vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Therapeutic effects of leuprorelin microspheres on endometriosis and uterine leiomyomata

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Induction of mucosal and systemic immune response by single-dose oral immunization with biodegradable microparticles containing DNA encoding HBsAg

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Intranasal vaccination against plague, tetanus and diphtheria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Analysis of local and systemic immunological responses after intra-tracheal, intra-nasal and intra-muscular administration of microsphere co-encapsulated Yersinia pestis sub-unit vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

New approach on the development of a mucosal vaccine against strangles: Systemic and mucosal immune responses in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Chimeric multiple antigenic peptides for simultaneous detection of specific antibodies to HIV-1 groups M, N, O, and HIV-2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Definition of a human suppressor T-cell epitope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Vaccine engineering: enhancement of immunogenicity of synthetic peptide vaccines related to hepatitis in chemically defined models consisting of T- and B-cell epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Lack of H-2 restriction of the Plasmodium falciparum (NANP) sequence as multiple antigen peptide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Plasmodium falciparum polyoximes: highly immunogenic synthetic vaccines constructed by chemoselective ligation of repeat B-cell epitopes and a universal T-cell epitope of CS protein.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Toll-like receptors as potential therapeutic targets for multiple diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

TLR agonists regulate PDGF-B production and cell proliferation through TGF-beta/type I IFN crosstalk

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Enhanced T cell-independent antibody responses in c-Jun N-terminal kinase 2 (JNK2)-deficient B cells following stimulation with CpG-1826 and anti-IgM

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Stimulation and inhibition of FVIII-specific memory B-cell responses by CpG-B (ODN 1826), a ligand for Toll-like receptor 9.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Cutting edge: lung mucosal Th17-mediated responses induce polymeric Ig receptor expression by the airway epithelium and elevate secretory IgA levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.129

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2011.09.129

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41424509&oldid=2097597030"